Compression of ferric ammonium citrate into immediate-release tablets for canine and feline iron-deficiency management requires formulation strategies that address the API’s deliquescent behavior and high aqueous solubility. The veterinary drug substance is typically supplied as greenish-brown, hygroscopic powder with an iron assay of 16.5–18.5% w/w on the dried basis; this assay window, rather than a fixed API mass, controls the amount of AFC per dosage unit because elemental iron delivery must be adjusted after lot-specific titration. Tablet cores containing 20–40% w/w AFC are produced by wet granulation rather than direct compression; direct compression is disfavored because AFC particles exhibit poor flow and adhere to stainless steel tooling when residual moisture exceeds 2%. A typical development formula for a 30 mg elemental iron tablet uses 166.7 mg AFC at 18.0% iron assay in a 600 mg core, corresponding to 27.8% w/w API. The granulation binder is povidone K30 dissolved in isopropanol-water 95:5 v/v, added until a wet mass endpoint of 1.2–1.4 N·m torque on a 65 L high-shear mixer is reached. The wet mass is passed through a 1.2 mm conical mill and dried in a fluid-bed dryer with inlet air temperature 50–55°C and product bed temperature 35–40°C; drying is terminated at loss-on-drying 1.5–2.5%. Overdrying below 1.0% LOD increases friability and die-wall friction on the rotary tablet press, while residual moisture above 3.0% causes picking and black speck formation on the punch faces.

Compression is performed on a 27-station rotary tablet press equipped with a forced feeder and D-tooling; compression force is held at 10–15 kN, with ejection force monitored at ≤1,500 N. Ejection force excursions above 2,000 N correlate with residual moisture below 1.0% and require immediate addition of external lubrication with magnesium stearate 0.75% w/w or tooling polish. Cores are sub-coated with 3% weight gain of hydroxypropyl methylcellulose 6 mPa·s solution before application of a colored film coat; the sub-coat functions as a moisture barrier, not as a rate-controlling membrane. Final tablets are packaged in cold-form aluminum/PVC blisters with a desiccant sachet because the film-coated cores remain hygroscopic and may darken when stored above 25°C/60% RH. Stability batches are placed under VICH GL3(R) conditions at 25°C/60% RH and 40°C/75% RH; the API-related degradation products are monitored by a stability-indicating HPLC method because the compendial titration method is not stability-indicating for citrate-ligand breakdown products.

What Limits Dissolution Kinetics of Ferric Ammonium Citrate in Drinking-Water Powders for Neonatal Swine?

Water-soluble powders for oral dosing of neonatal pigs are compounded by dry blending AFC with anhydrous dextrose, citric acid, and silicon dioxide. Because AFC dissolves rapidly in water at 25°C with a solubility exceeding 1 g/mL, the rate-limiting step in field use is not intrinsic dissolution but powder wetting and dispersion. Addition ratios are calculated from the iron assay: a final dosing solution of 100 mg elemental iron per litre requires 556 mg AFC per litre at 18.0% iron content. For a 10 L bucket, a single-dose sachet contains 5.56 g AFC; the bulk powder is diluted with dextrose monohydrate to a sachet fill weight of 20 g, placing the API at 27.8% w/w. The blending sequence uses a 50 kg ribbon mixer with a 20 rpm agitator speed for 15 min, followed by a 500 µm conical mill to break soft agglomerates. Because AFC is deliquescent above 40% RH, the blending suite is maintained at 20–25°C and 30–35% RH, and the finished powder is filled into heat-sealed PET/aluminum/LDPE sachets with desiccant.

Reconstitution in field conditions frequently exposes the powder to hard water containing calcium and magnesium carbonates; citrate in the AFC molecule provides partial chelation, but water hardness above 250 mg/L CaCO₃ can reduce dissolution clarity. A practical stress test uses 10 L of 300 mg/L hard water at 15°C; the solution must pass through a 150 µm screen without residue. The powder is manufactured in an isolator with continuous desiccant dehumidification, and the sachet filling line uses a 12-lane vertical form-fill-seal machine with registered foil printing. Terminal product types include 20 g, 50 g, and 200 g sachets; bulk packs are restricted to 1 kg because repeated opening introduces moisture and accelerates caking. Residual solvent compliance is tested under VICH GL18 with limits for isopropanol ≤5000 ppm and ethanol ≤5000 ppm; microbial limits for oral powder are verified by USP <61> and <62> with total aerobic microbial count ≤10² CFU/g and absence of Escherichia coli.

When citrate-to-iron Molar Ratio Falls Below 2:1 in Aqueous Parenteral Compounding

Injectable formulations containing ferric ammonium citrate occupy a narrow formulation space because the citrate ligand is the primary stabilizer against ferric hydroxide precipitation. In water for injection, AFC dissolves to form a clear reddish-brown solution; however, dilution beyond the complexation capacity or pH excursion above 7.5 generates colloidal Fe(OH)₃ that cannot be removed by a 0.22 µm membrane without significant iron loss. A workable parenteral concentration is 1–2% w/v AFC, equivalent to 1.8–3.6 mg elemental iron per mL at an iron assay of 18.0%. The citrate-to-iron molar ratio is maintained above 2:1 by adding citric acid monohydrate at 0.1–0.3% w/v as a buffering ligand; sodium hydroxide 0.1 N is used for pH adjustment to 5.5–6.5. The solution is sparged with nitrogen for 20 min before aseptic filtration because dissolved oxygen accelerates darkening and free-iron release. Terminal steam sterilization at 121°C for 15 min is not universally compatible with AFC solutions; published stability data for this specific veterinary configuration are limited, and a forced-degradation study must be conducted before terminal sterilization is selected. Where heat sterilization is unproven, the batch is filtered through a 0.22 µm PVDF filter and filled into Type I borosilicate amber vials under nitrogen overlay.

Phosphate-buffered diluents are incompatible with AFC parenteral solutions because ferric phosphate precipitates immediately, and normal saline should be qualified before use because chloride ions can accelerate color shift and free-iron release. The formulation vessel is equipped with a dissolved-oxygen probe; oxygen content is held below 0.5 mg/L during compounding. Filterability tests are run with a 47 mm disk at constant pressure 0.5 bar; a filtration flux decline greater than 30% over 100 L/m² indicates ligand dissociation or particle formation and requires batch rejection. The vial headspace is flushed with nitrogen to residual oxygen below 2% before stoppering. Terminal product types are 10 mL single-dose amber glass ampoules and 50 mL multi-dose vials with chlorobutyl rubber stoppers; multi-dose formulations contain benzyl alcohol 0.9% w/v as a preservative unless the species is feline, for which benzyl alcohol is contraindicated. Compliance for parenteral veterinary products includes USP <1> Injections, USP <71> Sterility Tests, USP <85> Bacterial Endotoxins, and USP <788> Particulate Matter in Injections; VICH GL3(R) stability storage at 25°C/60% RH and 40°C/75% RH is used to assign shelf life. Container-closure integrity is validated by dye ingress under USP <1207>, and the stability program includes particulate matter testing rather than relying solely on compendial monograph limits.

Capsule-based delivery of ferric ammonium citrate for companion animals is selected when gastric irritation from rapid iron release must be limited by multiparticulate coating. Hard hydroxypropyl methylcellulose capsules are filled with AFC-containing pellets produced by extrusion-spheronization; the API is granulated with microcrystalline cellulose, lactose monohydrate, and povidone K30 at a dry-mix ratio of 30% w/w AFC, 45% MCC, 20% lactose, and 5% povidone. The wet mass is extruded through a 0.8 mm screen in a twin-screw extruder with an L/D ratio of 20:1, spheronized at 800–1,000 rpm for 3–5 min, and dried in a fluid-bed dryer to ≤2.0% LOD. The pellets are then coated with an enteric methacrylic acid copolymer dispersion, Eudragit L 30 D-55, at 10–15% weight gain in a Wurster column at product temperature 25–28°C. The coating prevents ferric iron release in the gastric environment, which is relevant because Fe³⁺ ions can exacerbate gastric irritation in cats and small dogs. Capsule filling uses a 40,000 capsule/h dosator-type machine with pellet fill weight 250 mg for a 30 mg elemental iron dose; the AFC assay is 18.0%, and the pellet fraction contains 75 mg AFC per capsule.

Pellet dissolution is evaluated by USP <711> apparatus II at 50 rpm in 750 mL of 0.1 N HCl for 2 h, followed by pH adjustment to 6.8 phosphate buffer; the enteric-coated pellets should release not more than 10% in acid and not less than 75% in buffer within 45 min. The capsule fill weight is monitored by in-line checkweigher with rejection limits of ±3% around target; pellet loss on drying is held at ≤2.0% to avoid HPMC capsule shell embrittlement. Terminal product types are size 2 HPMC capsules in cold-form aluminum blister strips; for feline dosing, the capsule can be opened and pellets sprinkled on food, but the enteric coating must remain intact, and the product is labeled against chewing. Compliance is anchored to USP <905> for weight variation, USP <711> for two-stage dissolution, and VICH GL3(R) for stability; elemental impurities are tested by USP <232>/<233> with PDE limits for oral veterinary products.

Feed-Grade Granulation, Segregation Control, and Prescription-Medicated Premix Platforms

Granular premixes containing ferric ammonium citrate for swine and poultry are manufactured by wet granulation of the API onto a carrier to prevent segregation of high-density AFC particles from lighter organic carriers. In a 1% inclusion premix targeting 150 mg elemental iron per kg of final feed, the premix must contain 83.3 g AFC per kg, or 8.33% w/w, at an iron assay of 18.0%. The granulation vehicle is a 2–3% w/w aqueous solution of modified lignosulfonate or pregelatinized starch, sprayed onto a blend of AFC, wheat bran, and calcium carbonate in a fluid-bed granulator with inlet air at 55–60°C. The resulting granules are sieved to 200–800 µm and blended with antioxidant-stabilized vegetable oil at 0.5% w/w to control dust and moisture uptake. Pneumatic conveying is conducted only with dried air at a dew point below −10°C because AFC fines adhere to conveying line walls above 35% RH.

Premix granulation binds AFC to the carrier and reduces fine-particle segregation, but overgranulation above 800 µm causes poor distribution in feed because large granules survive mixing and are sorted by auger systems. The medicated feed mill must demonstrate a coefficient of variation for iron distribution below 10% across 10 sampled locations in a 2-tonne batch; this is measured by atomic absorption spectroscopy after acid digestion. Carry-over validation uses a flush batch of ground corn and requires residual iron carry-over below 1% of the active batch concentration. Compliance for medicated feed premises is anchored to EU 2019/4 on medicated feed, EU 183/2005 feed hygiene, and FAMI-QS v6.0 for specialty feed ingredients; where the premix is produced under veterinary prescription, the downstream feed mill must perform flush batches and carry-over validation. Terminal product types are 5 kg and 25 kg moisture-barrier bags with a sift-proof inner liner; the label must state the veterinary prescription requirement and the elemental iron concentration per kg.

Oral drench solutions for cattle and calves are prepared by dissolving AFC in deionized water to a final concentration of 50–100 g/L, equivalent to 9–18 g elemental iron per litre. The solution is compounded in a 500 L jacketed stainless steel vessel at 20–25°C with a high-torque propeller mixer; citric acid is added at 0.5–1.0 g/L to suppress ferric hydrolysis, and sodium benzoate 0.1% w/v is used as a preservative for multi-dose containers. Packaging is in 1 L and 5 L high-density polyethylene jugs with induction-sealed caps; light-protected storage is required because AFC solutions darken under UV exposure. Compliance is verified under USP <61>/<62> and VICH GL18; the terminal product is a ready-to-use oral drench solution.